title: S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13).
abstract: Adjuvant chemotherapy by S-1 following gastrectomy is considered standard treatment in Japan. Analysis of follow-up data have proved the efficacy of S-1 administration, and that hematological adverse events were relatively rare. Pyrimidine anti-metabolites, including S-1, have shown relatively lower risks for secondary hematological malignancies in comparison to alkylating agents and topoisomerase-II inhibitors. We here report a case of therapy-related leukemia after S-1 administration. A patient who had received S-1as the sole adjuvant chemotherapy was diagnosed with acute erythroid leukemia. To the best of our knowledge, our patient represents the first report of S-1 induced acute leukemia.
authors.affiliation: First Department of Internal Medicine, Kagawa Univesity, 1750-1 Miki-cho, Kita-gun, Kagawa prefecture 761-0793, Japan. matsumot@med.kagawa-u.ac.jp
authors.forename: Kensuke
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Akira
authors.initials: A
authors.lastname: Kitanaka
authors.forename: Makiko
authors.initials: M
authors.lastname: Uemura
authors.forename: Fusako
authors.initials: F
authors.lastname: Waki
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Fukumoto
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ohnishi
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Kubota
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishida
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D007446:Chromosome Inversion; D004338:Drug Combinations; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000235:genetics* / Q000473:pathology; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics*; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid